PBPK models for the prediction of in vivo performance of oral dosage forms

European Journal of Pharmaceutical Sciences

Volumn 57, Issue 1, 2014, Pages 300-321

  Kostewicz, Edmund S ^a   Aarons, Leon ^b   Bergstrand, Martin ^c   Bolger, Michael B ^d   Galetin, Aleksandra ^b   Hatley, Oliver ^b   Jamei, Masoud ^e   Lloyd, Richard ^f   Pepin, Xavier ^g   Rostami Hodjegan, Amin ^b,e   Sjögren, Erik ^c   Tannergren, Christer ^h   Turner, David B ^e   Wagner, Christian ^a   Weitschies, Werner ⁱ   Dressman, Jennifer ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d Simulations Plus Inc   (United States)

^e CERTARA UK LIMITED   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

^g SANOFI   (France)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Gastrointestinal physiology; In vitro biopharmaceutical tools; Innovative Medicines Initiative (IMI); Oral Biopharmaceutical Tools (OrBiTo); Physiologically based pharmacokinetic (PBPK) models; Predicting drug absorption

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG; DRUG DOSAGE FORM;

ACTIVE TRANSPORT; ADVANCED COMPARTMENTAL ABSORPTION TRANSIT MODEL; ADVANCED DISSOLUTION ABSORPTION AND MODEL; ARTICLE; BIOLOGICAL MODEL; BODY FLUIDS AND SECRETIONS; BODY SURFACE; COMPARTMENT MODEL; COMPUTER PROGRAM; DIFFUSION COEFFICIENT; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG SOLUBILITY; ENTEROHEPATIC CIRCULATION; ENZYME ACTIVITY; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; GASTROPLUS MODEL; GI SIM MODEL; HUMAN; HYDRODYNAMICS; INTESTINAL WALL METABOLISM; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; INTESTINE WALL; LIVER MICROSOME; MECHANICAL STRESS; MEMBRANE TRANSPORT; METABOLIC CAPACITY; NONHUMAN; ORAL DRUG ABSORPTION; PARTICLE SIZE; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PK SIM MODEL; PRECIPITATION; PRIORITY JOURNAL; SIMULATOR; SOLUBILIZATION; STELLA MODEL; STOMACH EMPTYING; STOMACH PH; ANIMAL; CHEMISTRY; DRUG DOSAGE FORM; GASTROINTESTINAL TRACT; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; PHARMACEUTICS; PHARMACOKINETICS; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY;

EID: 84899940075     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.09.008     Document Type: Review

References (233)

1. B. Abrahamsson, M. Alpsten, U.E. Jonsson, P.J. Lundberg, A. Sandberg, M. Sundgren, A. Svenheden, and J. Tölli Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon Int. J. Pharm. 140 1996 229 235
2. B.S. Abuasal, M.B. Bolger, D.K. Walker, and A. Kaddoumi In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate Mol. Pharm. 9 2012 492 504
3. D.A. Adkin, S.S. Davis, R.A. Sparrow, and I.R. Wilding Colonic transit of different sized tablets in healthy subjects J. Control. Release 23 1993 147 156
4. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Deliv. Rev. 50 Suppl. 1 2001 S41 S67
5. P. Apostolopoulos, C. Liatsos, I.M. Gralnek, E. Giannakoulopoulou, G. Alexandrakis, C. Kalantzis, P. Gabriel, and N. Kalantzis The role of wireless capsule endoscopy in investigating unexplained iron deficiency anemia after negative endoscopic evaluation of the upper and lower gastrointestinal tract Endoscopy 38 2006 1127 1132
6. Y.E. Arnold, G. Imanidis, and M.T. Kuentz Advancing in-vitro drug precipitation testing: new process monitoring tools and a kinetic nucleation and growth model J. Pharm. Pharmacol. 63 2011 333 341
7. D. Ashiru, R. Patel, and A. Basit Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females Pharm. Res. 25 2008 2327 2333
8. A. Avdeef Solubility of sparingly-soluble ionizable drugs Adv. Drug Deliv. Rev. 59 2007 568 590
9. A. Avdeef, C.M. Berger, and C. Brownell PH-metric solubility. 2: Correlation between the acid-base titration and the saturation shake-flask solubility-pH methods Pharm. Res. 17 2000 85 89
10. A. Avdeef, S. Bendels, L. Di, B. Faller, M. Kansy, K. Sugano, and Y. Yamauchi PAMPA - critical factors for better predictions of absorption J. Pharm. Sci. 96 2007 2893 2909
11. V. Bakatselou, R.C. Oppenheim, and J.B. Dressman Solubilization and wetting effects of bile salts on the dissolution of steroids Pharm. Res. 8 1991 1461 1469
12. J.S. Barrett, O. Della Casa Alberighi, S. Läer, and B. Meibohm Physiologically Based Pharmacokinetic (PBPK) modeling in children Clin. Pharmacol. Ther. 92 2012 40 49
13. Z.E. Barter, M.K. Bayliss, P.H. Beaune, A.R. Boobis, D.J. Carlile, R.J. Edwards, J.B. Houston, B.G. Lake, J.C. Lipscomb, O.R. Pelkonen, G.T. Tucker, and A. Rostami-Hodjegan Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver Curr. Drug Metab. 8 2007 33 45
14. L.M. Berezhkovskiy Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics J. Pharm. Sci. 93 2004 364 374
15. L.M. Berezhkovskiy Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination J. Pharm. Sci. 93 2004 1628 1640
16. S. Berggren, C. Gall, N. Wollnitz, M. Ekelund, U. Karlbom, J. Hoogstraate, D. Schrenk, and H. Lennernas Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine Mol. Pharm. 4 2007 252 257
17. M. Bergstrand, E. Söderlind, W. Weitschies, and M.O. Karlsson Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics Clin. Pharmacol. Ther. 86 2009 77 83
18. Bergström, A.S.; Holm, R.; Jørgensen, S.A.; Andersson, S.B.E.; Artursson, P.; Beato, S.; Borde, A.; Box, K.; Brewster, M.; Dressman, J.; Feng, K.; Halbert, G.; Kostewicz, E.; McAllistar, M.; Muenster, U.; Thinnes, J.; Taylor, R.; Müllertz, A.; 2013. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. Eur. J. Pharm. Sci.; submitted for publiciation.
19. M. Bergstrand, E. Soderlind, U.G. Eriksson, W. Weitschies, and M.O. Karlsson A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations Pharm. Res. 29 2012 695 706
20. M. Bergstrand, E. Söderlind, U.G. Eriksson, W. Weitschies, and M.O. Karlsson A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations Pharm. Res. 29 2012 574 584
21. C.A. Bergstrom, K. Luthman, and P. Artursson Accuracy of calculated pH-dependent aqueous drug solubility Eur. J. Pharm. Sci. 22 2004 387 398
22. J. Bevernage, J. Brouwers, P. Annaert, and P. Augustijns Drug precipitation-permeation interplay: supersaturation in an absorptive environment Eur. J. Pharm. Biopharm. 82 2012 424 428
23. K.B. Bischoff, and R.L. Dedrick Thiopental pharmacokinetics J. Pharm. Sci. 57 1968 1346 1351
24. K.B. Bischoff, R.L. Dedrick, D.S. Zaharko, and J.A. Longstreth Methotrexate pharmacokinetics J. Pharm. Sci. 60 1971 1128 1133
25. I. Bjarnason, A. MacPherson, and D. Hollander Intestinal permeability: an overview Gastroenterology 108 1995 1566 1581
26. S. Björkman Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs Br. J. Clin. Pharmacol. 59 2005 691 704
27. F. Bouzom, K. Ball, N. Perdaems, and B. Walther Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm. Drug Dispos. 33 2012 55 71
28. A. Bowles, J. Keane, T. Ernest, D. Clapham, and C. Tuleu Specific aspects of gastro-intestinal transit in children for drug delivery design Int. J. Pharm. 395 2010 37 43
29. S.T. Buckley, K.J. Frank, G. Fricker, and M. Brandl Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations" Eur. J. Pharm. Sci. 50 2013 8 16
30. N.R. Budha, A. Frymoyer, G.S. Smelick, J.Y. Jin, M.R. Yago, M.J. Dresser, S.N. Holden, L.Z. Benet, and J.A. Ware Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 92 2012 203 213
31. P.J. Bungay, S. Tweedy, D.C. Howe, K.R. Gibson, H.M. Jones, and N.M. Mount Pre-clinical and clinical pharmacokinetics of PF-02413873, a non-steroidal progesterone receptor antagonist Drug Metab. Dispos. 2011
32. S. Carlert, A. Palsson, G. Hanisch, C. von Corswant, C. Nilsson, L. Lindfors, H. Lennernas, and B. Abrahamsson Predicting intestinal precipitation - a case example for a basic BCS class II drug Pharm. Res. 27 2010 2119 2130
33. P.L. Carver, D. Fleisher, S.Y. Zhou, D. Kaul, P. Kazanjian, and C. Li Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients Pharm. Res. 16 1999 718 724
34. H.S. Chen, and J.F. Gross Physiologically based pharmacokinetic models for anticancer drugs Cancer Chemother. Pharmacol. 2 1979 85 94
35. Y.Y. Chiu, K. Higaki, B.L. Neudeck, J.L. Barnett, L.S. Welage, and G.L. Amidon Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells Pharm. Res. 20 2003 749 756
36. K. Claassen, S. Willmann, T. Eissing, T. Preusser, and M. Block A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine renin-angiotensin-aldosterone system Front. Physiol. 4 2013 4
37. A.J. Coupe, S.S. Davis, D.F. Evans, and I.R. Wilding Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility Pharm. Res. 8 1991 1281 1285
38. A.J. Coupe, S.S. Davis, D.F. Evans, and I.R. Wilding The effect of sleep on the gastrointestinal transit of pharmaceutical dosage forms Int. J. Pharm. 78 1992 69 76
39. A.J. Coupe, S.S. Davis, D.F. Evans, and I.R. Wilding Nocturnal scintigraphic imaging to investigate the gastrointestinal transit of dosage forms J. Control. Release 20 1992 155 162
40. J.R. Crison, P. Timmins, A. Keung, V.V. Upreti, D.W. Boulton, and B.J. Scheer Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling J. Pharm. Sci. 101 2012 1773 1782
41. H.E. Cubitt, J.B. Houston, and A. Galetin Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance Pharm. Res. 26 2009 1073 1083
42. H.E. Cubitt, J.B. Houston, and A. Galetin Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data Drug Metab. Dispos. 39 2011 864 873
43. D.J. Cutler On the definition of the compartment concept in pharmacokinetics J. Theor. Biol. 73 1978 329 345
44. A.S. Darwich, S. Neuhoff, M. Jamei, and A. Rostami-Hodjegan Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model Curr. Drug Metab. 11 2010 716 729
45. A.S. Darwich, D. Pade, B.J. Ammori, M. Jamei, D.M. Ashcroft, and A. Rostami-Hodjegan A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution J. Pharm. Pharmacol. 64 2012 1008 1024
46. S.S. Davis, J.G. Hardy, and M.J. Taylor A comparative study of the gastrointestinal transit of a pellet and tablet formulation Int. J. Pharm. 21 1984 167 177
47. S.S. Davis, J.G. Hardy, and J.W. Fara Transit of pharmaceutical dosage forms through the small intestine Gut 27 1986 886 892
48. S.S. De Buck, V.K. Sinha, L.A. Fenu, R.A. Gilissen, C.E. Mackie, and M.J. Nijsen The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools Drug Metab. Dispos. 35 2007 649 659
49. I. de Waziers, P.H. Cugnenc, C.S. Yang, J.P. Leroux, and P.H. Beaune Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues J. Pharmacol. Exp. Ther. 253 1990 387 394
50. I. De Wever, C. Eeckhout, G. Vantrappen, and J. Hellemans Disruptive effect of test meals on interdigestive motor complex in dogs Am. J. Physiol. 1978 235
51. R.L. Dedrick, and K.B. Bischoff Pharmacokinetics in applications of the artificial kidney Chem. Eng. Prog. Symp. Ser. 64 1968 32 44
52. A. Diakidou, M. Vertzoni, K. Goumas, E. Soderlind, B. Abrahamsson, J. Dressman, and C. Reppas Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults Pharm. Res. 26 2009 2141 2151
53. K. Dickschen, S. Willmann, K. Thelen, J. Lippert, G. Hempel, and T. Eissing Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance Front. Pharmacol. 3 2012 92
54. A. Dokoumetzidis, L. Kalantzi, and N. Fotaki Predictive models for oral drug absorption: from in silico methods to integrated dynamical models Exp. Opin. Drug Metab. Toxicol. 3 2007 491 505
55. C.P. Dooley, C. Di Lorenzo, and J.E. Valenzuela Variability of migrating motor complex in humans Dig. Dis. Sci. 37 1992 723 728
56. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 11 Suppl. 2 2000 S73 80
57. J.B. Dressman, R.R. Berardi, L.C. Dermentzoglou, T.L. Russell, S.P. Schmaltz, J.L. Barnett, and K.M. Jarvenpaa Upper gastrointestinal (GI) pH in young, healthy men and women Pharm. Res. 7 1990 756 761
58. J.B. Dressman, M. Vertzoni, K. Goumas, and C. Reppas Estimating drug solubility in the gastrointestinal tract Adv. Drug Deliv. Rev. 59 2007 591 602
59. I.S. Edelmann, and J. Liebmann Anatomy of body water and electrolytes Am. J. Med. 27 1959 256 277
60. M. Efentakis, and J.B. Dressman Gastric juice as a dissolution medium: surface tension and pH Eur. J. Drug Metab. Pharmacokinet. 23 1998 97 102
61. T. Eissing, L. Kuepfer, C. Becker, M. Block, K. Coboeken, T. Gaub, L. Goerlitz, J. Jaeger, R. Loosen, B. Ludewig, M. Meyer, C. Niederalt, M. Sevestre, H.U. Siegmund, J. Solodenko, K. Thelen, U. Telle, W. Weiss, T. Wendl, S. Willmann, and J. Lippert A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks Front. Physiol. 2 2011 4
62. T. Eissing, J. Lippert, and S. Willmann Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition Mol. Diagn. Ther. 16 2011 43 53
63. Y. Fei, E.S. Kostewicz, M.T. Sheu, and J.B. Dressman Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach Eur. J. Pharm. Biopharm. 2013
64. N. Fotaki, M. Symillides, and C. Reppas In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis Eur. J. Pharm. Sci. 24 2005 115 122
65. N. Fotaki, A. Aivaliotis, J. Butler, J. Dressman, M. Fischbach, J. Hempenstall, S. Klein, and C. Reppas A comparative study of different release apparatus in generating in vitro-in vivo correlations for extended release formulations Eur. J. Pharm. Biopharm. 73 2009 115 120
66. A.C. Freire, A.W. Basit, R. Choudhary, C.W. Piong, and H.A. Merchant Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery Int. J. Pharm. 415 2011 15 28
67. A. Galetin, and J.B. Houston Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism J. Pharmacol. Exp. Ther. 318 2006 1220 1229
68. A. Galetin, M. Gertz, and J.B. Houston Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions Drug Metab. Pharmacokinet. 25 2010 28 47
69. C. Gaynor, A. Dunne, and J. Davis The effects of averaging on accuracy of IVIVC model predictions J. Pharm. Sci. 98 2009 3829 3838
70. M. Gertz, A. Harrison, J.B. Houston, and A. Galetin Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Drug Metab. Dispos. 38 2010 1147 1158
71. M. Gertz, J.B. Houston, and A. Galetin Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction Drug Metab. Dispos. 39 2011 1633 1642
72. M. Gertz, C.M. Cartwright, M.J. Hobbs, K.E. Kenworthy, M. Rowland, J.B. Houston, and A. Galetin Application of PBPK modeling in the assessment of the interaction potential of cyclosporine against hepatic and intestinal uptake and efflux transporters and CYP3A4 Pharm. Res. 30 2013 761 780
73. A. Glomme, J. März, and J.B. Dressman Predicting the Intestinal Solubility of Poorly Soluble Drugs. Pharmacokinetic Profiling in Drug Research 2007 Wiley-VCH Verlag GmbH & Co. KGaA pp. 259-280
74. J.D. Gomez-Mantilla, V.G. Casabo, U.F. Schaefer, and C.M. Lehr Permutation Test (PT) and Tolerated Difference Test (TDT): two new, robust and powerful nonparametric tests for statistical comparison of dissolution profiles Int. J. Pharm. 441 2013 458 467
75. G.M. Grass, and W.T. Morehead Evidence for site-specific absorption of a novel ACE inhibitor Pharm. Res. 6 1989 759 765
76. C.H. Gu, D. Rao, R.B. Gandhi, J. Hilden, and K. Raghavan Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility J. Pharm. Sci. 94 2005 199 208
77. M.D. Harwood, S. Neuhoff, G.L. Carlson, G. Warhurst, and A. Rostami-Hodjegan Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption Biopharm. Drug Dispos. 34 2012 2 28
78. A.T. Heikkinen, G. Baneyx, A. Caruso, and N. Parrott Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus Eur. J. Pharm. Sci. 47 2012 375 386
79. A.T. Heikkinen, A. Friedlein, J. Lamerz, P. Jakob, P. Cutler, S. Fowler, T. Williamson, R. Tolando, T. Lave, and N. Parrott Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dog Pharm. Res. 29 2012 1832 1842
80. C. Hilgendorf, G. Ahlin, A. Seithel, P. Artursson, A.L. Ungell, and J. Karlsson Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines Drug Metab. Dispos. 35 2007 1333 1340
81. E. Husebye The patterns of small bowel motility: physiology and implications in organic disease and functional disorders Neurogastroenterol. Motil. 11 1999 141 161
82. K. Ito, K. Ogihara, S. Kanamitsu, and T. Itoh Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes Drug Metab. Dispos. 31 2003 945 954
83. M. Jamei, G.L. Dickinson, and A. Rostami-Hodjegan A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates Drug Metab. Pharmacokinet. 24 2009 53 75
84. M. Jamei, D. Turner, J. Yang, S. Neuhoff, S. Polak, A. Rostami-Hodjegan, and G. Tucker Population-based mechanistic prediction of oral drug absorption AAPS J. 11 2009 225 237
85. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 2008 1663 1676
86. E.J. Jeong, Y. Liu, H. Lin, and M. Hu Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10 Drug Metab. Dispos. 33 2005 785 794
87. T.N. Johnson, K. Boussery, K. Rowland-Yeo, G.T. Tucker, and A. Rostami-Hodjegan A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance Clin. Pharmacokinet. 49 2010 189 206
88. H.M. Jones, P.L. Chan, P.H. van der Graaf, and R. Webster Use of modelling & simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for Hepatitis C Br. J. Clin. Pharmacol. 2011
89. H.M. Jones, I.B. Gardner, W.T. Collard, P.J. Stanley, P. Oxley, N.A. Hosea, D. Plowchalk, S. Gernhardt, J. Lin, M. Dickins, S.R. Rahavendran, B.C. Jones, K.J. Watson, H. Pertinez, V. Kumar, and S. Cole Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling Clin. Pharmacokinet. 50 2011 331 347
90. H.M. Jones, H.A. Barton, Y. Lai, Y.A. Bi, E. Kimoto, S. Kempshall, S.C. Tate, A. El-Kattan, J.B. Houston, A. Galetin, and K.S. Fenner Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data Drug Metab. Dispos. 40 2012 1007 1017
91. D. Juenemann, E. Jantratid, C. Wagner, C. Reppas, M. Vertzoni, and J.B. Dressman Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles Eur. J. Pharm. Biopharm. 77 2011 257 264
92. L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J.B. Dressman, and C. Reppas Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies Pharm. Res. 23 2006 165 176
93. L. Kalantzi, E. Persson, B. Polentarutti, B. Abrahamsson, K. Goumas, J.B. Dressman, and C. Reppas Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents Pharm. Res. 23 2006 1373 1381
94. J.C. Kalvass, and G.M. Pollack Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition Pharm. Res. 24 2007 265 276
95. A. Kambayashi, and J.B. Dressman An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: Case example dantrolene Eur J Pharm Biopharm 84 2013 200 207
96. Kambayashi, A.; Blume, H.; Dressman, J.; 2013. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac. Eur. J. Pharm. Biopharm. (accepted). Available at: http://www.sciencedirect.com/science/article/pii/ S0939641113003020.
97. M. Kataoka, K. Sugano, C. da Costa Mathews, J.W. Wong, K.L. Jones, Y. Masaoka, S. Sakuma, and S. Yamashita Application of dissolution/permeation system for evaluation of formulation effect on oral absorption of poorly water-soluble drugs in drug development Pharm. Res. 29 2012 1485 1494
98. J.L. Kaye Review of paediatric gastrointestinal physiology data relevant to oral drug delivery Int. J. Clin. Pharm. 33 2011 20 24
99. R. Khosla, and S.S. Davis The effect of tablet size on the gastric emptying of non-disintegrating tablets Int. J. Pharm. 62 1990 R9 R11
100. T. Knutson, P. Fridblom, H. Ahlstrom, A. Magnusson, C. Tannergren, and H. Lennernas Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography Mol. Pharm. 6 2009 2 10
101. G. Koren, H. Nordeng, and S. Macleod Gender differences in drug bioequivalence: time to rethink practices Clin. Pharmacol. Ther. 93 2013 260 262
102. K.R. Korzekwa, S. Nagar, J. Tucker, E.A. Weiskircher, S. Bhoopathy, and I.J. Hidalgo Models to predict unbound intracellular drug concentrations in the presence of transporters Drug Metab. Dispos. 40 2012 865 876
103. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51
104. E.S. Kostewicz, A. Abrahamsson, M. Brewster, J. Brouwers, J. Butler, S. Carlert, P.A. Dickinson, J.B. Dressman, R. Holm, S. Klein, J. Mann, M. McAllister, M. Minekus, U. Muenster, A. Müllertz, M. Verweij, M. Vertzoni, W. Weitschies, and P. Augustijns In vitro models for the prediction of in vivo performance of oral dosage forms Eur. J. Pharm. Sci. 57 2014 342 366
105. M. Koziolek, G. Garbacz, M. Neumann, and W. Weitschies Simulating the postprandial stomach: physiological considerations for dissolution and release testing Mol. Pharm. 2013 this issue
106. M. Kuentz, S. Nick, N. Parrott, and D. Rothlisberger A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study Eur. J. Pharm. Sci. 27 2006 91 99
107. H. Lennernas Intestinal permeability and its relevance for absorption and elimination Xenobiotica 37 2007 1015 1051
108. H. Lennernas, D. Nilsson, S.M. Aquilonius, O. Ahrenstedt, L. Knutson, and L.K. Paalzow The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man Br. J. Clin. Pharmacol. 35 1993 243 250
109. A. Lindahl, A.L. Ungell, L. Knutson, and H. Lennernas Characterization of fluids from the stomach and proximal jejunum in men and women Pharm. Res. 14 1997 497 502
110. L. Lindfors, S. Forssen, J. Westergren, and U. Olsson Nucleation and crystal growth in supersaturated solutions of a model drug J. Colloid Interface Sci. 325 2008 404 413
111. Lukacova, V.; Parrott, N.; Lave, T.; Fraczkiewicz, M.; Bolger, M.; Woltosz, W, 2008. General approach to calculation of tissue:plasma partition coefficients for physiologically based pharmacokinetic (PBPK) modeling. AAPS National Meeting, Atlanta, November 15-20.
112. V. Lukacova, W.S. Woltosz, and M.B. Bolger Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data AAPS J. 11 2009 323 334
113. P. Matsson, C.A. Bergstrom, N. Nagahara, S. Tavelin, U. Norinder, and P. Artursson Exploring the role of different drug transport routes in permeability screening J. Med. Chem. 48 2005 604 613
114. Y. Matsuda, Y. Konno, M. Satsukawa, T. Kobayashi, Y. Takimoto, K. Morisaki, and S. Yamashita Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats Drug Metab. Dispos. 40 2012 2231 2238
115. E.L. McConnell, H.M. Fadda, and A.W. Basit Gut instincts: explorations in intestinal physiology and drug delivery Int. J. Pharm. 364 2008 213 226
116. R. Mellaerts, R. Mols, P. Kayaert, P. Annaert, J. Van Humbeeck, G. Van den Mooter, J.A. Martens, and P. Augustijns Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport Int. J. Pharm. 357 2008 169 179
117. K. Menochet, K.E. Kenworthy, J.B. Houston, and A. Galetin Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model J. Pharmacol. Exp. Ther. 341 2012 2 15
118. T. Mirza, S.A. Bykadi, C.D. Ellison, Y. Yang, B.M. Davit, and M.A. Khan Use of in vitro-in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices Pharm. Res. 30 2013 179 190
119. S.D. Mithani, V. Bakatselou, C.N. TenHoor, and J.B. Dressman Estimation of the increase in solubility of drugs as a function of bile salt concentration Pharm. Res. 13 1996 163 167
120. S. Mouly, and M.F. Paine P-glycoprotein increases from proximal to distal regions of human small intestine Pharm. Res. 20 2003 1595 1599
121. D.M. Mudie, G.L. Amidon, and G.E. Amidon Physiological parameters for oral delivery and in vitro testing Mol. Pharm. 7 2010 1388 1405
122. I.A. Nestorov, L.J. Aarons, P.A. Arundel, and M. Rowland Lumping of whole-body physiologically based pharmacokinetic models J. Pharmacokinet. Biopharm. 26 1998 21 46
123. S. Neuhoff, A.L. Ungell, I. Zamora, and P. Artursson PH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions Pharm. Res. 20 2003 1141 1148
124. S. Neuhoff, K.R. Yeo, Z. Barter, M. Jamei, D.B. Turner, and A. Rostami-Hodjegan Application of permeability-limited physiologically-based pharmacokinetic models: Part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin J. Pharm. Sci. 102 2013 3161 3173
125. NHANES, 1997. In: Statistics, N.C.f.H. (Ed.), Third National Health and Nutrition Examination Survey (NHANES III). Hyattsville, MD.
126. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388
127. A.E. Nielsen Diffusion controlled growth of a moving sphere. The kinetics of crystal growth in potassium perchlorate precipitation J. Phys. Chem. 65 1961 46 49
128. W.S. Nimmo Drugs, diseases and altered gastric emptying Clin. Pharmacokinet. 1 1976 189 203
129. S.G. Nugent, D. Kumar, D.S. Rampton, and D.F. Evans Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs Gut 48 2001 571 577
130. S. Ohtsuki, O. Schaefer, H. Kawakami, T. Inoue, S. Liehner, A. Saito, N. Ishiguro, W. Kishimoto, E. Ludwig-Schwellinger, T. Ebner, and T. Terasaki Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities Drug Metab. Dispos. 40 2012 83 92
131. A. Okumu, M. DiMaso, and R. Lobenberg Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug Pharm. Res. 25 2008 2778 2785
132. R.E. Oliver, A.F. Jones, and M. Rowland What surface of the intestinal epithelium is effectively available to permeating drugs? J. Pharm. Sci. 87 1998 634 639
133. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh, J.D. Perkins, and K.E. Thummel Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J. Pharmacol. Exp. Ther. 283 1997 1552 1562
134. M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, and D.C. Zeldin The human intestinal cytochrome P450 "pie" Drug Metab. Dispos. 34 2006 880 886
135. K.S. Pang Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series) Drug Metab. Dispos. 31 2003 1507 1519
136. K.S. Pang, and E.C. Chow Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model Drug Metab. Dispos. 40 2012 1869 1877
137. N. Parrott, and T. Lave Applications of physiologically based absorption models in drug discovery and development Mol. Pharm. 5 2008 760 775
138. Patel, N.; Turner, D.B.; Polak, S.; Jamei, M.; Rostami-Hodjegan, A.; 2012a. Mechanistic Deconvolution using the ADAM Model: Part 1. Establishing Mechanistic IVIVC for Controlled Release Formulations of the High Extraction BCS Class I Drug Metoprolol: Comparison with Conventional IVIVC Models. AAPS, Chicago.
139. Patel, N.; Turner, D.B.; Polak, S.; Jamei, M.; Rostami-Hodjegan, A.; 2012b. Mechanistic Deconvolution Using the ADAM Model: Part 2. Designing a New Once Daily Formulation for Metoprolol based on Mechanistic IVIVC and Studying the Population Variability in its Pharmacokinetics. AAPS, Chicago.
140. Patel, N.; Polak, S.; Jamei, M.; Rostami-Hodjegan, A.; Turner, D.B.; 2014. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data using the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug Nifedipine. Eur. J. Pharm. Sci. 57, 240-249.
141. E.M. Persson, A.S. Gustafsson, A.S. Carlsson, R.G. Nilsson, L. Knutson, P. Forsell, G. Hanisch, H. Lennernas, and B. Abrahamsson The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids Pharm. Res. 22 2005 2141 2151
142. E.M. Persson, A.S. Gustafsson, A.S. Carlsson, R.G. Nilsson, L. Knutson, P. Forsell, G. Hanisch, H. Lennernäs, and B. Abrahamsson The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids Pharm. Res. 22 2005 2141 2151
143. E.M. Persson, R.G. Nilsson, G.I. Hansson, L.J. Lofgren, F. Liback, L. Knutson, B. Abrahamsson, and H. Lennernas A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine Pharm. Res. 23 2006 742 751
144. PK-Sim®, S.B.S.S.M.f.; 2012. Systems Biology Software Suite Manual for PK-Sim 5.1.3. Bayer Technology Services, Leverkusen, Germany. Bayer Technoloy Services GmbH, Leverkusen, Germany.
145. S. Polak Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp®V8) Drug Metab. Rev. 40 2008 45
146. J.W. Polli, S.A. Wring, J.E. Humphreys, L. Huang, J.B. Morgan, L.O. Webster, and C.S. Serabjit-Singh Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 299 2001 620 628
147. C.J. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248
148. C.J. Porter, C.W. Pouton, J.F. Cuine, and W.N. Charman Enhancing intestinal drug solubilisation using lipid-based delivery systems Adv. Drug Deliv. Rev. 60 2008 673 691
149. P. Poulin, and F.P. Theil A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery J. Pharm. Sci. 89 2000 16 35
150. P. Poulin, and F.P. Theil Prediction of pharmacokinetics prior to in vivo studies. I. Mechanism-based prediction of volume of distribution J. Pharm. Sci. 91 2002 129 156
151. P. Poulin, and F.P. Theil Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition J. Pharm. Sci. 91 2002 1358 1370
152. P. Poulin, K. Schoenlein, and F.P. Theil Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs J. Pharm. Sci. 90 2001 436 447
153. P. Poulin, R.D. Jones, H.M. Jones, C.R. Gibson, M. Rowland, J.Y. Chien, B.J. Ring, K.K. Adkison, M.S. Ku, H. He, R. Vuppugalla, P. Marathe, V. Fischer, S. Dutta, V.K. Sinha, T. Bjornsson, T. Lave, and J.W. Yates PHRMA CPCDC initiative on predictive models of human pharmacokinetics, Part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach J. Pharm. Sci. 2011
154. D. Psachoulias, M. Vertzoni, K. Goumas, V. Kalioras, S. Beato, J. Butler, and C. Reppas Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults Pharm. Res. 28 2011 3145 3158
155. D. Psachoulias, M. Vertzoni, J. Butler, D. Busby, M. Symillides, J. Dressman, and C. Reppas An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine Pharm. Res. 29 2012 3486 3498
156. S.K. Quinney, R.E. Galinsky, V.A. Jiyamapa-Serna, Y. Chen, M.A. Hamman, S.D. Hall, and R.E. Kimura Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats Drug Metab. Dispos. 36 2008 1097 1101
157. S.K. Quinney, X. Zhang, A. Lucksiri, J.C. Gorski, L. Li, and S.D. Hall Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin Drug Metab. Dispos. 38 2010 241 248
158. K.D. Raemsch, and J. Sommer Pharmacokinetics and metabolism of nifedipine Hypertension 5 1983 II18-24
159. Z. Riches, E.L. Stanley, J.C. Bloomer, and M.W. Coughtrie Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie" Drug Metab. Dispos. 37 2009 2255 2261
160. T. Rodgers, and M. Rowland Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J. Pharm. Sci. 95 2006 1238 1257
161. T. Rodgers, and M. Rowland Mechanistic approaches to volume of distribution predictions: understanding the processes Pharm. Res. 24 2007 918 933
162. T. Rodgers, D. Leahy, and M. Rowland Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 94 2005 1259 1276
163. T. Rodgers, D. Leahy, and M. Rowland Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat J. Pharm. Sci. 94 2005 1237 1248
164. A. Rostami-Hodjegan Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology Clin. Pharmacol. Ther. 92 2012 50 61
165. M. Rowland, C. Peck, and G. Tucker Physiologically-based pharmacokinetics in drug development and regulatory science Annu. Rev. Pharmacol. Toxicol. 51 2011 45 73
166. T.L. Russell, R.R. Berardi, J.L. Barnett, L.C. Dermentzoglou, K.M. Jarvenpaa, S.P. Schmaltz, and J.B. Dressman Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women Pharm. Res. 10 1993 187 196
167. R. Sadik, H. Abrahamsson, A. Kilander, and P.-O. Stotzer Gut transit in celiac disease: delay of small bowel transit and acceleration after dietary treatment Am. J. Gastroenterol. 99 2004 2429 2436
168. S.K. Sarna Cyclic motor activity; migrating motor complex: 1985 Gastroenterology 89 1985 894 913
169. G. Sathyan, S. Hwang, and S.K. Gupta Effect of dosing time on the total intestinal transit time of non-disintegrating systems Int. J. Pharm. 204 2000 47 51
170. C. Schiller, C.P. Fröhlich, T. Giessmann, W. Siegmund, H. Mönnikes, N. Hosten, and W. Weitschies Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging Aliment. Pharmacol. Ther. 22 2005 971 979
171. W. Schmitt General approach for the calculation of tissue to plasma partition coefficients Toxicol. In Vitro 22 2008 457 467
172. A. Shafik, O. El-Sibai, and A.A. Shafik Physiological assessment of the function of the ileocecal junction with evidence of ileocecal junction reflexes Med. Sci. Monit. 8 2002 CR629 CR635
173. Y. Shi, P. Gao, Y. Gong, and H. Ping Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption Mol. Pharm. 7 2010 1458 1465
174. Y. Shono, E. Jantratid, N. Janssen, F. Kesisoglou, Y. Mao, M. Vertzoni, C. Reppas, and J.B. Dressman Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling Eur. J. Pharm. Biopharm. 73 2009 107 114
175. Y. Shono, E. Jantratid, F. Kesisoglou, C. Reppas, and J.B. Dressman Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans Eur. J. Pharm. Biopharm. 76 2010 95 104
176. Y. Shono, E. Jantratid, and J.B. Dressman Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir Eur. J. Pharm. Biopharm. 79 2011 349 356
177. V.K. Sinha, J. Snoeys, N.V. Osselaer, A.V. Peer, C. Mackie, and D. Heald From preclinical to human-prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example Biopharm. Drug Dispos. 33 2012 111 121
178. P.J. Sinko, and P.V. Balimane Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats Biopharm. Drug Dispos. 19 1998 209 217
179. E. Sjögren, J. Westergren, I. Grant, G. Hanisch, L. Lindfors, H. Lennernäs, B. Abrahamsson, and C. Tannergren In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim Eur. J. Pharm. Sci. 2013
180. T. Sousa, R. Paterson, V. Moore, A. Carlsson, B. Abrahamsson, and A.W. Basit The gastrointestinal microbiota as a site for the biotransformation of drugs Int. J. Pharm. 363 2008 1 25
181. C.P. Strassburg, S. Kneip, J. Topp, P. Obermayer-Straub, A. Barut, R.H. Tukey, and M.P. Manns Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine J. Biol. Chem. 275 2000 36164 36171
182. A. Strougo, T. Eissing, A. Yassen, S. Willmann, M. Danhof, and J. Freijer First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development J. Pharmacokinet Pharmacodyn. 39 2012 195 203
183. K. Sugano Estimation of effective intestinal membrane permeability considering bile micelle solubilisation Int. J. Pharm. 368 2009 116 122
184. K. Sugano Introduction to computational oral absorption simulation Exp. Opin. Drug Metab. Toxicol. 5 2009 259 293
185. K. Sugano, A. Okazaki, S. Sugimoto, S. Tavornvipas, A. Omura, and T. Mano Solubility and dissolution profile assessment in drug discovery Drug Metab. Pharmacokinet. 22 2007 225 254
186. D. Sun, H. Lennernas, L.S. Welage, J.L. Barnett, C.P. Landowski, D. Foster, D. Fleisher, K.D. Lee, and G.L. Amidon Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs Pharm. Res. 19 2002 1400 1416
187. R. Takano, K. Sugano, A. Higashida, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test Pharm. Res. 23 2006 1144 1156
188. R. Takano, N. Takata, R. Saito, K. Furumoto, S. Higo, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita Quantitative analysis of the effect of supersaturation on in vivo drug absorption Mol. Pharm. 2010
189. Tanaka, G.; Kawamura, H.; 1996. Anatomical and Physiological Characteristics for Asian Reference Man: Male and Female Different Ages: Tanaka model. Division of Radioecology, National Institute of Radiological Sciences. Hitachinaka 311-12 Japan. Report Number NIRS-M-115.
190. T. Taupitz, J.B. Dressman, C.M. Buchanan, and S. Klein Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole Eur. J. Pharm. Biopharm. 83 2013 378 387
191. T. Teorell Kinetics of distribution of substances administered to the body. I The extravascular modes of administration Arch. Int. Pharmacodyn. Ther. 57 1937 205 225
192. T. Teorell Kinetics of distribution of substances administered to the body. I The intravascular modes of administration Arch. Int. Pharmacodyn. Ther. 57 1937 226 240
193. K. Thelen, E. Jantratid, J.B. Dressman, J. Lippert, and S. Willmann Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing J. Pharm. Sci. 99 2010 2899 2904
194. K. Thelen, K. Coboeken, S. Willmann, R. Burghaus, J.B. Dressman, and J. Lippert Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions J. Pharm. Sci. 100 2011 5324 5345
195. K. Thelen, K. Coboeken, S. Willmann, J.B. Dressman, and J. Lippert Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part II: Extension to describe performance of solid dosage forms J. Pharm. Sci. 101 2012 1267 1280
196. V.E. Thiel-Demby, J.E. Humphreys, L.A. St John Williams, H.M. Ellens, N. Shah, A.D. Ayrton, and J.W. Polli Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay Mol. Pharm. 6 2009 11 18
197. K.E. Thummel, D. O'Shea, M.F. Paine, D.D. Shen, K.L. Kunze, J.D. Perkins, and G.R. Wilkinson Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism Clin. Pharmacol. Ther. 59 1996 491 502
198. M. Tubic, D. Wagner, H. Spahn-Langguth, M.B. Bolger, and P. Langguth In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect Pharm. Res. 23 2006 1712 1720
199. T.G. Tucker, A.M. Milne, S. Fournel-Gigleux, K.S. Fenner, and M.W. Coughtrie Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum Biochem. Pharmacol. 83 2012 279 285
200. R.H. Tukey, and C.P. Strassburg Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract Mol. Pharmacol. 59 2001 405 414
201. Valentin, J.P.; 2002. Basic Anatomical and Physiological Data for use in Radiological Protection: Reference Values. A Report of Age- and Gender-related Differences in the Anatomical and Physiological Characteristics of Reference Individuals. ICRP Publication 89. Ann ICRP 32, 5-265.
202. A. Van den Bergh, V. Sinha, R. Gilissen, R. Straetemans, K. Wuyts, D. Morrison, L. Bijnens, and C. Mackie Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery Clin. Pharmacokinet. 50 2011 505 517
203. P.C. van Zijl, S.M. Eleff, J.A. Ulatowski, J.M. Oja, A.M. Ulug, R.J. Traystman, and R.A. Kauppinen Quantitative assessment of blood flow, blood volume and blood oxygenation effects in functional magnetic resonance imaging Nat. Med. 4 1998 159 167
204. M.V. Varma, R.S. Obach, C. Rotter, H.R. Miller, G. Chang, S.J. Steyn, A. El-Kattan, and M.D. Troutman Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination J. Med. Chem. 53 2010 1098 1108
205. F.J.O. Varum, H.A. Merchant, and A.W. Basit Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption Int. J. Pharm. 395 2010 26 36
206. M. Vertzoni, M. Symillides, A. Iliadis, E. Nicolaides, and C. Reppas Comparison of simulated cumulative drug versus time data sets with indices Eur. J. Pharm. Biopharm. 56 2003 421 428
207. O. von Richter, O. Burk, M.F. Fromm, K.P. Thon, M. Eichelbaum, and K.T. Kivisto Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens Clin. Pharmacol. Ther. 75 2004 172 183
208. J.G. Wagner History of pharmacokinetics Pharmacol. Ther. 12 1981 537 562
209. C. Wagner, E. Jantratid, F. Kesisoglou, M. Vertzoni, and C.J.B.D. Reppas Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model Eur. J. Pharm. Biopharm. 82 2012 127 138
210. Washington, C.; Washington, N.; Wilson, C.G.; 1990. Pharmacokinetic Modeling using STELLA on the Apple Macintosh. Ellis Horwood, Chichester, England.
211. Watson, K.J.; Davis, J.; Jones, H.M.; 2011. The Application of Physiologically Based Pharmacokinetic Modelling to Understanding the Clinical Pharmacokinetics of UK-369,003. Drug Metab Dispos.
212. O. Weber, S. Willmann, H. Bischoff, V. Li, A. Vakalopoulos, K. Lustig, F.T. Hafner, R. Heinig, C. Schmeck, and K. Buehner Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling Br. J. Clin. Pharmacol. 73 2012 219 231
213. W. Weitschies, R.S. Wedemeyer, O. Kosch, K. Fach, S. Nagel, E. Soderlind, L. Trahms, B. Abrahamsson, and H. Monnikes Impact of the intragastric location of extended release tablets on food interactions J. Control. Release 108 2005 375 385
214. W. Weitschies, H. Blume, and H. Mönnikes Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract Eur. J. Pharm. Biopharm. 74 2010 93 101
215. S. Willmann, W. Schmitt, J. Keldenich, and J.B. Dressman A physiologic model for simulating gastrointestinal flow and drug absorption in rats Pharm. Res. 20 2003 1766 1771
216. S. Willmann, W. Schmitt, J. Keldenich, J. Lippert, and J.B. Dressman A physiological model for the estimation of the fraction dose absorbed in humans J. Med. Chem. 47 2004 4022 4031
217. S. Willmann, A.N. Edginton, and J.B. Dressman Development and validation of a physiology-based model for the prediction of oral absorption in monkeys Pharm. Res. 24 2007 1275 1282
218. S. Willmann, A.N. Edginton, K. Coboeken, G. Ahr, and J. Lippert Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study Clin. Pharmacol. Ther. 86 2009 634 643
219. S. Willmann, A.N. Edginton, M. Kleine-Besten, E. Jantratid, K. Thelen, and J.B. Dressman Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption J. Pharm. Pharmacol. 61 2009 891 899
220. S. Willmann, K. Thelen, C. Becker, J.B. Dressman, and J. Lippert Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs Eur. J. Pharm. Biopharm. 76 2010 83 94
221. S. Winiwarter, N.M. Bonham, F. Ax, A. Hallberg, H. Lennernas, and A. Karlen Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach J. Med. Chem. 41 1998 4939 4949
222. W. Woodtli, and C. Owyang Duodenal pH governs interdigestive motility in humans Am. J. Physiol. 268 1995 G146 152
223. S. Yamazaki, J. Skaptason, D. Romero, S. Vekich, H.M. Jones, W. Tan, K.D. Wilner, and T. Koudriakova Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model Drug Metab. Dispos. 39 2011 383 393
224. J. Yang, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of intestinal first-pass drug metabolism Curr. Drug Metab. 8 2007 676 684
225. L.X. Yu Pharmaceutical quality by design: product and process development, understanding, and control Pharm. Res. 25 2008 781 791
226. L.X. Yu, and G.L. Amidon Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data Eur. J. Pharm. Biopharm. 45 1998 199 203
227. L.X. Yu, and G.L. Amidon A compartmental absorption and transit model for estimating oral drug absorption Int. J. Pharm. 186 1999 119 125
228. L.X. Yu, J.R. Crison, and G.L. Amidon Compartmental transit and dispersion model analysis of small intestinal transit flow in humans Int. J. Pharm. 140 1996 111 118
229. L.X. Yu, E. Lipka, J.R. Crison, and G.L. Amidon Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption Adv. Drug Deliv. Rev. 19 1996 359 376
230. K.H. Yuen The transit of dosage forms through the small intestine Int. J. Pharm. 395 1-2 2010 9 16
231. M.J. Zamek-Gliszczynski, C.A. Lee, A. Poirier, J. Bentz, X. Chu, T. Ishikawa, M. Jamei, J.C. Kalvass, S. Nagar, K.S. Pang, K. Korzekwa, P.W. Swaan, M.E. Taub, P. Zhao, and A. Galetin ITC recommendations on transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans Clin. Pharmacol. Ther. 2013
232. Q.Y. Zhang, D. Dunbar, A. Ostrowska, S. Zeisloft, J. Yang, and L.S. Kaminsky Characterization of human small intestinal cytochromes P-450 Drug Metab. Dispos. 27 1999 804 809
233. X. Zhang, S.K. Quinney, J.C. Gorski, D.R. Jones, and S.D. Hall Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite Drug Metab. Dispos. 37 2009 1587 1597